These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1395 related items for PubMed ID: 26170125

  • 1. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG, Lee CH, Lee WJ, Shin DH, Roh MS.
    Diagn Pathol; 2015 Jul 12; 10():99. PubMed ID: 26170125
    [Abstract] [Full Text] [Related]

  • 2. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
    Li H, Wang Y, Su F, Li J, Gong P.
    Int J Clin Exp Pathol; 2015 Jul 12; 8(5):5577-83. PubMed ID: 26191267
    [Abstract] [Full Text] [Related]

  • 3. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H, Yang JM, Jin Y, Jheon S, Kim K, Lee CT, Chung JH, Paik JH.
    Oncotarget; 2017 Jan 31; 8(5):8484-8498. PubMed ID: 28035073
    [Abstract] [Full Text] [Related]

  • 4. MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
    Shi SB, Wang M, Tian J, Li R, Chang CX, Qi JL.
    Transl Res; 2016 Apr 31; 170():1-7. PubMed ID: 26687391
    [Abstract] [Full Text] [Related]

  • 5. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G, Xie X, Sun D, Geng J, Fu F, Zhang L, Wang H.
    Int J Clin Exp Pathol; 2015 Apr 31; 8(7):8603-6. PubMed ID: 26339441
    [Abstract] [Full Text] [Related]

  • 6. MicroRNAs associated with increased AKT gene number in human lung carcinoma.
    Goto A, Dobashi Y, Tsubochi H, Maeda D, Ooi A.
    Hum Pathol; 2016 Oct 31; 56():1-10. PubMed ID: 27189341
    [Abstract] [Full Text] [Related]

  • 7. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC, Chen YM, Tseng CC, Huang KT, Wang CC, Chen YC, Lai CH, Fang WF, Kao HC, Lin MC.
    Tumour Biol; 2017 Mar 31; 39(3):1010428317695939. PubMed ID: 28351317
    [Abstract] [Full Text] [Related]

  • 8. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J, Zhang L, Zhu H, Pan W, Zhang N, Li Y, Yang M.
    DNA Cell Biol; 2018 Nov 31; 37(11):903-908. PubMed ID: 30277797
    [Abstract] [Full Text] [Related]

  • 9. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status.
    Dacic S, Kelly L, Shuai Y, Nikiforova MN.
    Mod Pathol; 2010 Dec 31; 23(12):1577-82. PubMed ID: 20818338
    [Abstract] [Full Text] [Related]

  • 10. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.
    Luo YH, Tseng PC, Lee YC, Perng RP, Whang-Peng J, Chen YM.
    Cancer Biomark; 2016 Dec 31; 16(1):19-29. PubMed ID: 26484608
    [Abstract] [Full Text] [Related]

  • 11. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK.
    Lung Cancer; 2014 Aug 31; 85(2):161-7. PubMed ID: 24857785
    [Abstract] [Full Text] [Related]

  • 12. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Jain A, Lim C, Gan EM, Ng DZ, Ng QS, Ang MK, Takano A, Chan KS, Tan WM, Kanesvaran R, Toh CK, Loo CM, Hsu AA, Devanand A, Lim CH, Koong HN, Koh T, Fong KW, Yap SP, Kim SW, Chowbay B, Oon L, Lim KH, Lim WT, Tan EH, Tan DS.
    PLoS One; 2015 Aug 31; 10(5):e0123587. PubMed ID: 25955322
    [Abstract] [Full Text] [Related]

  • 13. [Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma].
    Qian K, Zhang Y, Zhi X.
    Zhongguo Fei Ai Za Zhi; 2017 Aug 20; 20(8):543-548. PubMed ID: 28855035
    [Abstract] [Full Text] [Related]

  • 14. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY, Liu YN, Wu SG, Hsu CL, Chang TH, Tsai MF, Lin YT, Shih JY.
    Cancer Biomark; 2020 Aug 20; 28(3):351-363. PubMed ID: 32417760
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung.
    Nose N, Uramoto H, Iwata T, Hanagiri T, Yasumoto K.
    Lung Cancer; 2011 Mar 20; 71(3):350-5. PubMed ID: 20615575
    [Abstract] [Full Text] [Related]

  • 17. miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers.
    Remon J, Alvarez-Berdugo D, Majem M, Moran T, Reguart N, Lianes P.
    Clin Transl Oncol; 2016 Feb 20; 18(2):153-9. PubMed ID: 26199015
    [Abstract] [Full Text] [Related]

  • 18. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
    Pan JB, Hou YH, Zhang GJ.
    Clin Lab; 2014 Feb 20; 60(9):1439-47. PubMed ID: 25291939
    [Abstract] [Full Text] [Related]

  • 19. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
    Eng J, Woo KM, Sima CS, Plodkowski A, Hellmann MD, Chaft JE, Kris MG, Arcila ME, Ladanyi M, Drilon A.
    J Thorac Oncol; 2015 Dec 20; 10(12):1713-9. PubMed ID: 26334752
    [Abstract] [Full Text] [Related]

  • 20. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
    Kawana S, Saito R, Miki Y, Kimura Y, Abe J, Sato I, Endo M, Sugawara S, Sasano H.
    Cancer Med; 2021 Jan 20; 10(2):718-727. PubMed ID: 33305905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.